

Biocon Biologics France S.A.S**BALANCE SHEET AS AT MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2025</u>	<u>March 31, 2024</u>
ASSETS			
Non-current assets			
Property, plant and equipment		155	-
Right to use assets		569	-
Total non-current assets		724	-
Current assets			
Inventories	1	12,587	7,406
Financial assets			
(i) Trade receivables	2	9,424	16,679
(ii) Cash and cash equivalents	3	6,641	1,062
(iii) Other Financial Asset	4	1	1
Other current assets	5	171	-
Total current assets		28,824	25,148
TOTAL		29,548	25,148
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	1	1
Other equity	7	1,444	353
Total equity		1,445	354
Non-current liabilities			
Lease liabilities		432	-
Total current liabilities		432	-
Current liabilities			
Financial liabilities			
(i) Trade payables	8	26,495	23,864
(ii) Lease liability		153	-
Income-tax liability (net)		365	118
Provisions	9	372	209
Other current liabilities	10	287	605
Total current liabilities		27,672	24,796
TOTAL		29,548	25,148

Biocon Biologics France S.A.S

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	Year ended March 31, 2025	Period ended March 31, 2024
Income			
Revenue from operations	11	74,171	23,382
Other operating income	12	52	-
Total revenue (I)		74,223	23,382
Expenses			
Purchases of traded goods	13	64,466	26,005
Changes in inventories of traded goods	14	(5,181)	(7,406)
Employee benefits expense	15	6,019	2,324
Depreciation		79	-
Finance costs		23	-
Other expenses	17	7,363	1,989
Total expenses (II)		72,769	22,912
Profit before tax		1,454	470
Tax expense			
Current tax		275	118
Deferred Tax		88	-
Total tax expense		363	118
Profit for the year		1,091	353

Biocon Biologics France S.A.S
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
I Cash flows from operating activities		
Profit after tax	1,091	353
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Depreciation and amortisation (net)	79	-
Unrealised foreign exchange loss	52	-
Interest expense	23	-
Tax expense	363	118
Operating profit before working capital changes	1,608	470
Movements in working capital		
Decrease / (Increase) in trade receivables	7,260	(16,680)
(Increase) in trade inventories	(5,181)	(7,406)
(Increase) in loans and advances and other assets	(171)	-
Increase in trade payable, other liabilities and provisions	2,476	24,674
Cash generated from operations	5,992	1,058
Direct taxes paid	(116)	-
Net cash flow generated from operating activities	5,876	1,058
II Cash flows from investing activities		
Purchase of tangible assets	(155)	-
Net cash flow (used in) investing activities	(155)	-
III Cash flows from financing activities		
Repayment of lease liabilities	(87)	-
Net cash flow (used in) financing activities	(87)	1
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	5,634	1,059
V Effect of exchange differences on cash and cash equivalents held in foreign currency	(52)	-
VI Cash and cash equivalents at the beginning of the year	1,059	-
VII Cash and cash equivalents at the end of the year (IV + V + VI)	6,641	1,059
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	6,641	1,059
	6,641	1,059
Total cash and cash equivalents [Refer note 3]	6,641	1,059

Biocon Biologics France S.A.S**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2025	March 31, 2024
1. Inventories		
Finished Goods	12,587	7,406
	12,587	7,406
2. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment	9,426	16,679
Unsecured, considered good	9,424	16,679
3. Cash and cash equivalents		
Balances with banks:		
On current accounts	6,641	1,062
	6,641	1,062
4 . Other Financial Assets		
Other Receivables	1	1
	1	1
5. Other current assets		
Advance to suppliers	7	-
Prepayments	6	-
VAT Receivable	158	-
	171	-
6. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
1,000 Equity shares of EUR 1 each	1	1
	1	1
7. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	353	-
Profit / (Loss) for the period	1,091	353
Net surplus/(deficit) in the statement of profit and loss	1,444	353
Total other equity	1,444	353
8. Trade payables	26,495	23,864
9. Provisions		
Current		
Compensated absences	372	209
	372	209
10. Other liabilities		
Current liabilities		
Statutory liabilities	287	605
	287	600

Biocon Biologics France S.A.S**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
11. Revenue from operations		
Sale of Products		
Traded Goods	72,716	23,383
Sale of Services		
Support service cross charge to Group Companies	1,455	-
	74,171	23,382
12. Other operating income		
Foreign exchange fluctuations, net	52	-
	52	-
13. Purchase of traded goods	64,466	26,005
	64,466	26,005
14. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	7,406	-
Inventory at the end of the year		
Traded goods	12,587	7,406
	(5,181)	(7,406)
15. Employee benefits expense		
Salaries, wages and bonus	5,992	2,306
Employee stock compensation expense	11	-
Staff welfare expenses	16	19
	6,019	2,324
16. Finance Costs		
Interest on lease obligation	23	-
	23	-
17. Other expenses		
Rates and taxes	44	-
Rent	137	-
Legal and professional fees	467	44
Repair and Maintenance	144	-
Travelling and conveyance	483	188
Selling expenses	874	285
Sales promotion expenses	4,793	1,369
Printing and stationery	5	55
Communication expenses	3	-
Miscellaneous expenses	437	48
Insurance Charges	(24)	-
	7,363	1,989